- Total Pro Portfolios with NVS:
- Edgemoor Capital
- Fidelity Select Pharmaceuticals FPHAX
- Kinetics Medical MEDRX
- Edward Owens
- WisdomTree Intl Consumer Non-Cyclical Fund (DPN)
- Manning & Napier Pro-Blend Consrv Term A (EXDAX)
- Mainstay ICAP Select - ISRC
- Manning & Napier World Opportunities A - EXWAX
- show more
- 16
- Manning & Napier Tax Managed A - EXTAX
- TA IDEX Evergreen Health Care A LW IRHAX
- Dodge & Cox
- Allegiant Large Cap Core Equity B (ARCEX)
- Vanguard PRIMECAP - VPMCX
- Vanguard International Value (VTRIX)
- Vanguard PRIMECAP Core - VPCCX
- Oakmark International Fund (OAKIX)
- Total Do-It-Yourself Portfolios with NVS:
- certii Portfolio 1
- Doug Portfolio 1
- house of pain
- Spectacular portfolio
- cathy curtis Portfolio 1
- Andreas Portfolio 1
- Ekmekji
- JKaiden Portfolio 1
- Carrick312 watchlist
- ten picks for ten years
- First One by JiMi G
- Main Book
- Annenette 2007
- Ron Ferguson Portfolio 1
- wayneman Portfolio 1
- fred1 Portfolio 1
- Coneshark Portfolio 1
- cwcastle
- Vito Manzella Portfolio 1
- Solid Big Earners
- dkhang
- xima Portfolio 1
- fern
- rwhitr Portfolio 1
- Mark Van Patten Portfolio 1
- C R's Portfolio
- pinaki's stock portfolio
- Jack Peters Portfolio 1
- DLB
- Cause
- Mainstreet for solid appreciation
- Testnum portfolio
- Jim Vergas Portfolio 1
- Companies to Watch
- HC Stocks
- Profitable Fliers
- Follow up
- Brieža saraksts
- Lissa Portfolio 1
- Pam Lesher Portfolio 1
- Tom's port64
- principalportfolio
- C. Thompson Portfolio 1
- Diversfied
- Flash's Stocks
- my Roth
- poppy9
- alrenwald Portfolio 1
- nails4shelley Portfolio 1
- patient performer
- pmcveigh Portfolio 1
- show more
- 389
- sreeni chilakala Portfolio 1
- Pat Gannon Portfolio 1
- TT
- Samuel F. Zion Portfolio 1
- mami
- Luvie Portfolio 1
- Joe Lee Portfolio 1
- Barrons Healthcare picks
- Joshua Feldman Portfolio 1
- mph1
- dgopal Portfolio 1
- Miracle Gro
- CuPorfolio
- CountryBoy Portfolio 1
- Jay Man Portfolio 1
- Karl's SD IRA
- 1/8/07
- Stepko Portfolio 1
- newyear
- Ellen's Portfolio
- 5 Breakthrough Drugs for 2007
- All Cap Equity
- messina
- Jim Bob's Portfolio
- MPPort
- skehan Portfolio 1
- Collis
- g7test
- LeeG Portfolio 1
- rfaith Portfolio 1
- Walden's Stocks Owned
- My sell list
- PEMIRROR
- Just Thinking...
- Wells Trade Account
- Nittany Fan's Portfolio 1
- madmauer 1
- jesse s hogg Portfolio 1
- RBTERRY 2007
- IRA Portfolio
- suspectacts Portfolio 1
- tlsmitty1
- Jim McKinney Portfolio 1
- CM Dog Portfolio 1
- mmmmm
- Delta Chi GSC Portfolio 1
- gvandyke Portfolio 1
- pk2007mal Portfolio 1
- bobycecilia Portfolio 1
- Zenka Stocks
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- Incyte Passes 52-Week ...
- Novartis Says Weak IP ...
- China Is Growth Market...
- Week in Review: Major ...
- Novartis Joins Global ...
- show more
- 25/11/09
- 13/11/09
- 08/11/09
- 08/11/09
- 05/11/09
Why I Love This Stock |
|
By:barrons3 |
Date:11 21 09 |
The Basel, Switzerland-based firm's American depositary receipts have a dividend yield of 3.2%, and the payout has risen, on average, 15% annually over the past five years. At less than 12 times consensus 2010 earnings estimates of 4.63 Swiss francs ($4.55), Novartis is cheap, compared with the market P/E and its own average historical multiple of 18. While investors fret about the coming loss of patent, in 2011, on best-selling blood-pressure medication Diovan, sales of new drugs such as Galvus for diabetes and Tekturn for hypertension are building. In the near term, Novartis's H1N1, or swine flu, vaccine should boost results. Novartis' agreement to buy Alcon before August 2011 from Nestlé at a potentially rich price also worries some investors. But Novartis is good at cutting costs, and its sales are likely to keep growing in the high single digits. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:11 11 09 |
Seymour was keen to hear Novartis (NVS) is investing $1 billion to build the largest pharmaceutical research plant in China, emphasizing the importance of developing markets for future growth. Novartis said it was also investing $250 million in a second research and development and manufacturing facility in Changshu. I like the direction Novartis is taking, adds Pete Najarian. |
|
Not yet rated
Rate now:
|
|
Date:09 01 09 |
|
solid, successful |
|
Not yet rated
Rate now:
|
|
By:ghbogen |
Date:08 24 09 |
above average industrial strength earnings per share growth 9% |
|
Not yet rated
Rate now:
|
|
Date:02 28 09 |
|
Raised its 2009 dividend by 25% from 1.60 Swiss Francs a share to 2.00, the 12th increase since the company was founded in 1996. |
|
Not yet rated
Rate now:
|
|
By:JiMi G |
Date:12 07 08 |
07-DEC'08: Novartis is a solid (if boring) pharmaceutical company with a wise management team. They have easily out-performed the S&P 500 performance over the last 6 months. This is the 2nd company recommended by The Motley Fool to do well under the Obama administration. Price/share @ start = $47.13 |
|
Not yet rated
Rate now:
|
|
By:Milliemagoo |
Date:12 03 08 |
Proven to be a steady holding in this market |
|
Not yet rated
Rate now:
|
|
By:RAPTOR I |
Date:11 28 08 |
Novartis (NYSE: NVS) |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Amgen Builds Body of Evidence for Bone Drug: Elizabeth Trotta talks to Glenn Begley, vice president for hematology oncology research at Amgen, about potential blockbuster bone drug denosumab. |
|
Not yet rated
Rate now:
|
|
By:barrons3 |
Date:11 12 08 |
Najarian also said keep an eye on Johnson & Johnson(JNJ), Novartis(NVS) and Myriad Genetics(MYGN). |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
By:dumper |
Date:02 27 07 |
drug potential |
|
Not yet rated
Rate now:
|
|








